Page 1

RENISHAW apply innovation ™ Final Results Released : 21 Oct 2021 RNS Number : 7373P Renishaw PLC 21 October 2021 Renishaw plc 21 October 2021 Preliminary announcement of results for the year ended 30 June 2021 Summary • Revenue was £ 565.6m , 11 % higher than 2020 revenue of £ 510.2m . • A positive year of recovery . • • Strong growth in APAC throughout the year , with improving sales in EMEA and Americas in H2 . Manufacturing technologies ( formerly Metrology ) revenue increased by 11 % to £ 526.2m , with : • • record demand for encoders , driven by booming semiconductor and electronics capital investment ; rising sales of flexible gauging and machine tool products , especially in the consumer electronics sector ; and lower additive manufacturing sales , in line with expectations following restructuring in 2020 . • Analytical instruments and medical devices ( formerly Healthcare ) revenue increased by 12 % to £ 39.4m , with : . • general recovery in spectroscopy investment and increasing adoption of the Virsa ™ Raman Analyzer ; and growth in neurological products , as we support large pharmaceutical customers with clinical trials using our unique drug delivery technology . Adjusted * profit before tax of £ 119.7m ( 2020 : £ 48.6m ) , an increase of 146 % . • Statutory profit was £ 139.4m compared with £ 3.2m last year . • Our Fit for the Future initiative drove productivity improvements . • Adjusted profit before tax for the year increased to 21 % of revenue ( 2020 : 10 % ) ; for H2 it was 25 % . • Strong balance sheet , with net cash and bank deposits of £ 215.0m at 30 June 2021 , compared with £ 120.4m at 30 June 2020 . Our priorities during this pandemic continue to be the health and welfare of our employees , their families and the wider communities in which we operate , and to maintain high service levels to our global customer base . • A formal sale process , which commenced in March 2021 , was concluded in July with no suitable offers that satisfactorily met the interests of all stakeholders . " We have recovered well and our employees have shown great resilience in maintaining supply and excellent levels of support to our customers around the world . I am excited about our new products in development and the opportunities presented by global market trends . " Sir David McMurtry , Executive Chairman 2021 2020 Change Revenue ( £ m ) 565.6 510.2 Adjusted * profit before tax ( £ m ) 119.7 48.6 + 11 % + 146 % Adjusted * earnings per share ( pence ) 139.4 51.0 + 4,256 % Dividend per share ( pence ) 66.0 0.0 Statutory profit before tax ( £ m ) 139.4 3.2 Statutory earnings per share ( pence ) 153.2 0.4 * Note 28 , ' Alternative performance measures ' , defines how adjusted profit before tax , adjusted earnings per share , adjusted operating profit and revenue at constant exchange rates are calculated .